We are live on ! Find out more
FCMI

Foresite Capital Management IV Portfolio holdings

AUM $290M
1-Year Est. Return 143.88%
This Fund
S&P 500
This Quarter Est. Return
+28.22%
1 Year Est. Return
+143.88%
3 Year Est. Return
+150.93%
5 Year Est. Return
+74.33%
10 Year Est. Return
–
AUM
$290M
AUM Growth
+$53.1M
Cap. Flow
-$4.71M
Cap. Flow %
-1.62%
Top 10 Hldgs %
100%
Holding
9
New
1
Increased
2
Reduced
–
Closed
3

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$15.2M
2
CRNX
Crinetics Pharmaceuticals
CRNX
+$5.58M
3
RLAY icon
Relay Therapeutics
RLAY
+$3.63M

Top Sells

Rank Stock Value
1
LYEL icon
Lyell Immunopharma
LYEL
+$16.1M
2
ALEC icon
Alector
ALEC
+$8.36M
3
MAZE
Maze Therapeutics
MAZE
+$4.68M

Sector Composition

Rank Sector Weight
1 Healthcare 100%

No holdings matched the selected filter criteria.

Similar funds

NWP
NerdWallet Wealth Partners New York $290M AUM 17.69% 1-Year Est. Return
BCP
Bayberry Capital Partners New York $290M AUM 37.97% 1-Year Est. Return
NC
Nokomis Capital Dallas, Texas $290M AUM 55.12% 1-Year Est. Return
KLCMU
Kite Lake Capital Management (UK) London, United Kingdom $290M AUM 183.72% 1-Year Est. Return
SIA
SGL Investment Advisors Missoula, Montana $290M AUM 28.62% 1-Year Est. Return
MPWS
McCarter Private Wealth Services Boston, Massachusetts $290M AUM 33.25% 1-Year Est. Return
RC
Resolute Capital Greenville, South Carolina $290M AUM
VG
Visualize Group New York $291M AUM 12.24% 1-Year Est. Return

Foresite Capital Management IV's Q2 2026 Portfolio in Review

As of Q2 2026, Foresite Capital Management IV held 9 positions worth $290M, up 22% from $237M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management IV's Q2 2026 filing shows 1 new, 2 increased and 3 closed positions. Its largest new stake was Crinetics Pharmaceuticals: 150,000 shares worth $5.61M. The largest sale was Lyell Immunopharma, an estimated $16.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Foresite Capital Management IV's largest Q2 2026 buy was Crinetics Pharmaceuticals: 150,000 shares worth $5.61M.
  • Foresite Capital Management IV added most to Cytokinetics in Q2 2026, an estimated $15.2M increase.
  • Foresite Capital Management IV fully exited Lyell Immunopharma in Q2 2026, selling an estimated $16.1M.
  • Foresite Capital Management IV's ten largest holdings make up 100% of its $290M portfolio in Q2 2026.
  • Foresite Capital Management IV opened 1 new position and closed 3 in Q2 2026.
  • Foresite Capital Management IV's portfolio value rose 22% quarter-over-quarter to $290M.

Based on Foresite Capital Management IV's 13F filing for Q2 2026, filed 14 Aug 2026.